Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed in connection with modification of procaspases such as procaspase-3. In embodiments, compositions are capable of activation of procaspase-3.

Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed in connection with modification of procaspases such as procaspase-3. In embodiments, compositions are capable of activation of procaspase-3.

The present invention refers to a process for preparing amines comprising reacting a compound of the formula R.sup.1COR.sup.2 comprising a carbonyl moiety with a amine compound of the formula HNR.sup.3R.sup.4 and carbon monoxide in the presence of a catalyst.

The present invention refers to a process for preparing amines comprising reacting a compound of the formula R.sup.1COR.sup.2 comprising a carbonyl moiety with a amine compound of the formula HNR.sup.3R.sup.4 and carbon monoxide in the presence of a catalyst.

Provided are compounds of Formula (I):

##STR00001## or a pharmaceutically acceptable salt thereof, wherein Ring A, Ring B, L, R.sup.B, R.sup.C, n, and p are as defined herein.

Also provided are pharmaceutically acceptable compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Provided are compounds of Formula (I):

##STR00001## or a pharmaceutically acceptable salt thereof, wherein Ring A, Ring B, L, R.sup.B, R.sup.C, n, and p are as defined herein.

Also provided are pharmaceutically acceptable compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Also provided are methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Disclosed herein are addition-polymerizable monomer composition including an amine-derivatized alpha-methyl styrene (ADAMS) monomer according to structure (I) and/or an aminated conjugated aliphatic methylated polyene (ACAMP) monomer according to structure (II):

##STR00001##

with k, R.sub.1, R.sub.2, R.sub.3, and R.sub.4 defined herein. Difunctional monomers of these types with two polymerizable loci and/or two amine loci are also disclosed herein. Further disclosed herein are methods for making such compositions.

Disclosed herein are addition-polymerizable monomer composition including an amine-derivatized alpha-methyl styrene (ADAMS) monomer according to structure (I) and/or an aminated conjugated aliphatic methylated polyene (ACAMP) monomer according to structure (II):

##STR00001##

with k, R.sub.1, R.sub.2, R.sub.3, and R.sub.4 defined herein. Difunctional monomers of these types with two polymerizable loci and/or two amine loci are also disclosed herein. Further disclosed herein are methods for making such compositions.

A novel compound for a light emitting device, and an organic light emitting device containing the same are disclosed. The compound for a light emitting device is represented by Formula 1 below:

##STR00001##

Methods and compositions are provided for synthesizing ionic liquids from lignin. Methods and compositions are also provided for treating lignin with ionic liquids.